

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: 02-456-A1)

In re Application of:)
)
Varghese John) Examiner: Sahar Javanmard
)
Serial No.: 10/519,793)
) Art Unit: 1617
Filed: August 25, 2005)
) Confirmation No.: 3057
For: Methods for Treating)
Alzheimer's Disease Using)
Hydroxyethylene Compounds)
Containing a Heterocyclic Amide)
Bond Isostere)

RESPONSE TO THE RESTRICTION REQUIREMENT
MAILED NOVEMBER 28, 2007

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Responsive to the Restriction Requirement mailed November 28, 2007, the Applicants elect the claims of Group I, i.e., claims 1-6 and 20, for prosecution.

To comply with the requirement for species elections, the Applicants further elect as follows:

with respect to a disease from the list in claim 5: Alzheimer's disease; and

with respect to a compound: benzyl (S)-1-((2S,3S,5R)-3-hydroxy-5-(5-isobutyryl-1H-imidazol-2-yl)-1,6-diphenylhexan-2-ylamino)-3-methyl-1-oxobutan-2-ylcarbamate.

The above-identified compound species is the first compound listed in claim 6 and can be represented by the following structural formula:



The claims that read on the species of Alzheimer's disease are claims 1-6 and 20.

The claims that read on the compound species identified above are claims 1-6 and 20.

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-2136 if the Examiner believes that this would expedite prosecution of this application.

December 20, 2007

Respectfully submitted,

By: /Steven J. Sarussi/

Steven J. Sarussi
Reg. No. 32784

McDonnell Boehnen
Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-2136